Halozyme Therapeutics Inc

Halozyme’s acquisition of Elektrofi expands its ultra‑high concentration drug‑delivery platform, boosting royalty revenue and speeding biologics into market.

Halozyme Therapeutics Inc. is facing market headwinds due to downgrades and concerns over pricing controls, but some analysts remain optimistic about its long-term potential.

Halozyme Therapeutics Inc’s stock price plummeted due to new Medicare policies affecting drug pricing negotiations, leading to analyst downgrades and concerns over price control risks.

Halozyme Therapeutics Inc. has seen its stock value plummet due to regulatory headwinds, including Medicare’s new pricing strategy and analyst downgrades, casting a shadow over its future growth prospects.

Halozyme Therapeutics Inc. has filed a patent infringement lawsuit against Merck over its injectable formulation of cancer immunotherapy drug Keytruda.